JPH0135828B2 - - Google Patents

Info

Publication number
JPH0135828B2
JPH0135828B2 JP55136781A JP13678180A JPH0135828B2 JP H0135828 B2 JPH0135828 B2 JP H0135828B2 JP 55136781 A JP55136781 A JP 55136781A JP 13678180 A JP13678180 A JP 13678180A JP H0135828 B2 JPH0135828 B2 JP H0135828B2
Authority
JP
Japan
Prior art keywords
carnosine
formula
water
aluminum
ring proton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55136781A
Other languages
Japanese (ja)
Other versions
JPS5762263A (en
Inventor
Susumu Okabe
Takashi Sonehara
Masaru Sato
Mitsuo Mazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Priority to JP55136781A priority Critical patent/JPS5762263A/en
Publication of JPS5762263A publication Critical patent/JPS5762263A/en
Publication of JPH0135828B2 publication Critical patent/JPH0135828B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は次の一般式() (式中、Rは炭素数2〜6の低級アルキル基、フ
エニル基または低級アルコキシフエニル基を表わ
す。) で表わされるN―アシルカルノシンアルミニウム
塩に関する。 近年、消化性潰瘍患者は増加する傾向にあり、
その治療剤の開発のために種々の研究が行われて
いる。 そこで本発明者らは、多くの化合物を合成し、
その薬理効果を検討したところ、上記式()で
表わされるN―アシルカルノシンアルミニウム塩
が極めて優れた消化性潰瘍治療効果を有すること
を見出し、本発明を完成した。 従つて、本発明の目的は新規なN―アシルカル
ノシンアルミニウム塩を提供せんとするにある。 本発明のN―アシルカルノシンアルミニウム塩
は例えば、N―アシルカルノシンにアルミニウム
アルコキシドを反応せしめることにより製造され
る。 N―アシルカルノシンとしてはD―体、L―
体、DL―体が使用される。また、アルミニウム
アルコキシドとしては、アルミニウムメトキシ
ド、アルミニウムエトキシド、アルミニウムイソ
プロポキシド、アルミニウムt―ブトキシド、ア
ルミニウムシクロヘキシルオキシド等が使用され
る。このアルミニウムアルコキシドが水酸化アル
ミニウム又はその重合体等の不純物を含んでいる
場合には、蒸留、溶媒抽出等によつて不純物を除
去したものを使用するのが好ましい。 反応は、適当な溶媒中、室温ないし80℃の温度
で行うのが好ましい。適当な溶媒中、室温ないし
80℃の温度で行うのが好ましい。溶媒としては、
水又はメタノール、エタノール、イソプロパノー
ル、ブタノール等の有機溶媒あるいはこれらの混
和物が使用される。反応後、反応液から溶媒及び
副生するアルコール類を除去すれば、目的物
()が単離される。 次に、本発明のN―アシルカルノシンアルミニ
ウム塩について、その消化性潰瘍治療効果を試験
した結果を示す。尚、比較対照化合物として従来
抗潰瘍作用を有することが知られているN―アセ
チル―L―グルタミンアルミニウム塩、蔗糖硫酸
エステルアルミニウム塩を用いた。 実験 1 幽門結紮潰瘍に対する作用: 体重210〜230gのドンリユウ系雄ラツトを1群
10匹とした。Stayら(Gastroenterology、5、
43〜61、1945)の方法に従い48時間絶食し、エー
テル麻酔下に幽門部を結紮する。14時間絶食、絶
水下に放置し、胃をとり出し胃液を採取後、前胃
部に発生する潰瘍の面積(mm2)を解剖顕微鏡下
(10倍)にて計測し潰瘍指数として表わした。薬
物は幽門結紮直後に経口的に投与した。 結果を表1に示す。 【表】 以上の実験結果から明らかな如く、本発明のN
―アシルカルノシンアルミニウム塩は、潰瘍モデ
ルに対し優れた抑制効果を示す。すなわち、幽門
結紮潰瘍試験において、N―アシルカルノシンア
ルミニウム塩はラツトに1000/Kgを経口投与した
場合、潰瘍に対して、有意な抑制効果を示し、既
存の抗潰瘍剤と比較しても、同等若しくはそれ以
上の効果を示す。 以下、参考例及び実施例を挙げて本発明をさら
に具体的に説明するが、本発明はそれらに限定さ
れるものではない。 参考例 1 N―プロピオニル―L―カルノシン: L―カルノシン2.42gを水13mlで溶解し、アセ
トン6.5mlを加え、これを冷却し、20℃以下でPH
を7.0〜7.5に保ちながら、塩化プロピオニル4.14
gとトリエチルアミン7.6gを同時に約1時間を
要し滴下した。滴下終了後、減圧でアセトンを留
去し、強塩基性イオン交換樹脂(SA―10A)130
mlに吸着させ、水洗後1N酢酸で溶出させ、次に
強酸性イオン交換樹脂(SK―1B)10mlに吸着さ
せ水洗後2%アンモニア水で溶出させる。減圧濃
縮して、大部分のアンモニアを留去させ、次いで
弱酸性イオン交換樹脂(IRC―50)30mlに通過さ
せ、吸着されない部分を集め減圧乾固し粗結晶を
得る。これをメタノール―アセトン(2:3)の
混合溶媒で再結晶を行いN―プロピオニル―L―
カルノシンの白色結晶1.46g(収率48%)を得
た。 融点:206〜209℃(分解) 〔α〕25 D:+20.4゜(C=3%、水) IRνKBr naxcm-1:3300(OH)、1630(C=0)、1540、
1390 NMR(D2O)δ:1.06(3H、t、J=8Hz、―
CH2CH3 ) 2.18(2H、q、J=8Hz、―C
H2CH3) 2.44(2H、t、J=7Hz、―
NHCOCH2 CH2NH―) 3.14(2H、m、
【式】) 3.36(2H、t、J=7Hz、―
NHCOCH2CH2 NH―) 4.44(1H、m、
【式】) 7.08、8.48(1H×2、s×2、
イミタゾール環プロトン) 元素分析値 C12H18N4O4として 計算値(%) C:51.04、H:6.44、N:19.85 分析値(%) C:50.95、H:6.43、N:19.77 参考例 2 N―ヘプタノイル―L―カルノシン L―カルノシン2.42gを水13mlで溶解し、アセ
トン6.5mlを加え塩化プロピオニルに代え、塩化
ヘプタノイル6.36gを用い、参考例1と同様に、
イオン交換樹脂処理を行うことにより、粗結晶を
得る。これを水―アセトン(1:2)の混合溶媒
で再結晶を行うことにより、N―ヘプタノイル―
L―カルノシン1.66g(収率46%)を得た。 融点:214〜217℃(分解) 〔α〕25 D:+4.7゜=(C=2%、水) IRνKBr naxcm-1:3290、1635、1530、1400 NMR(D2O)δ:0.72(3H、m、―CH3 ) 0.86〜1.56(8H、m、
【式】) 2.06(2H、t、J=7Hz、―
COCH2 CH2―) 2.35(2H、t、J=7Hz、―
NHCOCH2 CH2NH) 2.94〜3.14(2H、m、
【式】) 3.26(2H、t、J=7Hz、―
NHCOCH2CH2 NH) 4.26〜4.44(1H、m、
【式】) 7.10、8.42(1H×2、s×2、
イミダゾール環プロトン) 元素分析値 C16H26N4O4として 計算値(%) C:56.77、H:7.76、N:16.56 分析値(%) C:56.81、H:7.85、N:16.38 参考例 3 N―ベンゾイル―L―カルノシン L―カルノシン2.42gを水13mlで溶解し、アセ
トン6.5mlを加え塩化プロピオニルに代え、塩化
ベンゾイル6.32gを用い、参考例1と同様にイオ
ン交換樹脂処理を行い得られた粗結晶をメタノー
ル―アセトンで再結晶を行いN―ベンゾイル―L
―カルノシン1.69g(収率48%)を得た。 融点:217〜219℃(分解) 〔α〕25 D:+10.3゜(C=1%、水) IRνKBr naxcm-1:3280、1640、1520、1385 NMR(D2O)δ:2.48(2H、t、J=7Hz、―
COCH2 CH2NH―) 3.02(2H、m、
【式】) 3.46(2H、t、J=7Hz、―
COCH2CH2 NH―) 4.37(1H、m、
【式】) 6.99〔1H、s、イミダゾール環
プロトン(5位)〕 7.1〜7.6(5H、m、ベンゼン環
プロトン) 8.14〔1H、s、イミダゾール環
プロトン(2位)〕 元素分析値 C16H18N4O4として 計算値(%) C:58.16、H:5.50、N:16.96 分析値(%) C:58.21、H:5.65、N:16.93 参考例 4 N―(O―メトキシ)ベンゾイル―L―カルノ
シン: L―カルノシン2.42gを水13mlに溶解し、アセ
トン6.5mlを加え、塩化プロピオニルに代え、塩
化O―メトキシベンゾイル7.67gを用い、参考例
1と同様にイオン交換樹脂処理を行い濃縮乾固す
る。この物質は非常に吸湿性で再結晶できず、粗
結晶を無水エーテルで洗浄して、白色粉末のN―
(O―メトキシベンゾイル)―L―カルノシン
1.54(収率40%)を得た。 融点:203℃(分解) 〔α〕25 D:7.6゜(C=1%、水) IRνKBr naxcm-1:3380、1630 NMR(CD3OD)δ:2.56(2H、t、J=7Hz、
―COCH2 CH2NH―) 3.16(2H、m、
【式】) 3.60(2H、t、J=7Hz、―
COCH2CH2 NH―) 3.86(3H、s、―OCH3 ) 4.55(1H、m、
【式】) 6.85〜7.85〔5H、m、ベンゼン
環プロトンとイミダゾール環プ
ロトン(2位)〕 8.33〔1H、s、イミダゾール環
プロトン(2位)〕 元素分析 C17H20N4O5として 計算値(%) C:56.65、H:5.60、N:15.55 分析値(%) C:56.61、H:5.58、N:15.61 実施例 1 アルミニウムイソプロポキシド0.80gを含むイ
ソプロピルアルコール11mlに、60℃でN―プロピ
オニル―L―カルノシン1.11gを加え、1時間撹
拌後、水10mlを加え30分間撹拌して均一な溶液と
した。その後、不溶物を別し、減圧下イソプロ
ピルアルコールを留去し、残留した水溶液を凍結
乾燥することにより、無色粉末のN―プロピオニ
ル―L―カルノシンアルミニウム塩1.3g(定量
的)を得た。 融点:228℃(分解) 〔α〕25 D:+11.4゜(C=3%、水) IRνKBr naxcm-1:3400(OH)、1640(C=0)、1540、
1400 NMR(D2O)δ:1.02(3H、t、CH3 CH2CO
―) 2.11(2H、q、CH3CH2 CO―) 2.40(2H、t、―COCH2
CH2NH―) 3.08(2H、m、
【式】) 3.28(2H、t、―COCH2CH2
NH―) 4.44(1H、m、
【式】) 7.07、8.26(1H×2、s×2、
イミダゾール環プロトン) 元素分析 (C12H17N4O4)Al(CH)2として 計算値(%) C:42.10、H:5.61、N:16.37 分析値(%) C:41.88、H:5.83、N:16.12 実施例 2 アルミニウムイソプロポキシド0.68gを含むイ
ソプロピルアルコール15mlにN―ヘプタノイル―
L―カルノシン1.13gを加え実施例1と同様に行
い、N―ヘプタノイル―L―カルノシンアルミニ
ウム塩の無色粉末1.3g(定量的)を得た。 融点:280℃以上 〔α〕25 D:+0.4゜(C=1%、水) IRνKBr naxcm-1:3400(OH)、2930、2860(アルキ
ル)、1640(C=0)、1540 NMR(D2O)δ:0.80(3H、t、CH3 ―CH2
―) 1.20(8H、m、―CH2―×4) 2.12(2H、t、―CH2CH2 CO
―) 2.40(2H、t、―COCH2
CH2NH―) 3.07(2H、m、
【式】) 3.31(2H、t、―COCH2CH2
NH―) 4.44(1H、m、
【式】) 7.06、8.28(1H×2、s×2、
イミダゾール環プロトン) 元素分析 C16H25N4O4)Al(OH)2として 計算値(%) C:48.23、H:6.84、N:14.06 分析値(%) C:48.03、H:6.87、N:13.77 実施例 3 アルミニウムイソプロポキシド0.8gを含むイ
ソプロピルアルコール15mlにN―ベンゾイル―L
―カルノシン1.27gを加え実施例1と同様に処理
し、N―ベンゾイル―L―カルノシンアルミニウ
ム塩の無色粉末1.5g(定量的)を得た。 融点:280℃以上 〔α〕25 D:+6.2゜(C=1%、H2O) IRνKBr naxcm-1:3400(OH)、1630(C=0)、1540、
1400 NMR(D2O)δ:2.55(2H、t、―COCH2
CH2NH―) 3.07(2H、m、
【式】) 3.55(2H、t、―COCH2CH2
NH―) 4.44(1H、m、
【式】) 6.99〔1H、s、イミダゾール環
プロトン(5位)〕 7.44(5H、m、ベンゼン環プロ
トン) 8.08〔1H、s、イミダゾール環
プロトン(2位)〕 元素分析 (C16H17N4O4)Al(OH)2として 計算値(%) C:49.23、H:4・92、N:
14.36 分析値(%) C:49.18、H:4.86、N:14.18 実施例 4 アルミニウムイソプロポキシド0.68gを含むイ
ソプロピルアルコール15mlにN―(O―メトキ
シ)ベンゾイル―L―カルノシン1.20gを加え実
施例1と同様に処理し、N―(O―メトキシ)―
L―カルノシンアルミニウム塩1.4g(定量的)
を得た。 融点:280℃以上 〔α〕25 D:+2.7゜(C=1%、水) IRνKBr naxcm-1:3400(OH)、1630(C=0)、1540、
1400、1310 NMR(D2O)δ:2.56(2H、t、―COCH2
CH2NH―) 3.29(2H、m、
【式】 3.55(2H、t、―COCH2CH2
NH―) 3.83(3H、s、―OCH3 ) 4.44(1H、m、
【式】) 6.95〜7.65(5H、m、ベンゼン
環プロトンとイミダゾール環プ
ロトン) 7.96(1H、s、イミダゾール環
プロトン) 元素分析 (C17H19N4O5)Al(OH)2 計算値(%) C:48.57、H:5.05、N:13.33 分析値(%) C:48.42、H:4.92、N:13.18
[Detailed Description of the Invention] The present invention is based on the following general formula () (In the formula, R represents a lower alkyl group having 2 to 6 carbon atoms, a phenyl group, or a lower alkoxyphenyl group.) In recent years, the number of peptic ulcer patients has been increasing.
Various studies are being conducted for the development of therapeutic agents. Therefore, the present inventors synthesized many compounds and
After examining its pharmacological effects, it was discovered that the N-acylcarnosine aluminum salt represented by the above formula () has an extremely excellent therapeutic effect on peptic ulcers, and the present invention was completed. Therefore, an object of the present invention is to provide a novel N-acylcarnosine aluminum salt. The N-acylcarnosine aluminum salt of the present invention is produced, for example, by reacting N-acylcarnosine with an aluminum alkoxide. N-acylcarnosine is D-form, L-
body, DL - body is used. Further, as the aluminum alkoxide, aluminum methoxide, aluminum ethoxide, aluminum isopropoxide, aluminum t-butoxide, aluminum cyclohexyl oxide, etc. are used. When this aluminum alkoxide contains impurities such as aluminum hydroxide or its polymer, it is preferable to use one from which the impurities have been removed by distillation, solvent extraction, etc. The reaction is preferably carried out in a suitable solvent at a temperature of room temperature to 80°C. in a suitable solvent at room temperature to
Preferably it is carried out at a temperature of 80°C. As a solvent,
Water or organic solvents such as methanol, ethanol, isopropanol, butanol, or mixtures thereof are used. After the reaction, by removing the solvent and by-product alcohols from the reaction solution, the desired product () can be isolated. Next, the results of testing the peptic ulcer therapeutic effect of the N-acylcarnosine aluminum salt of the present invention will be shown. Note that N-acetyl-L-glutamine aluminum salt and sucrose sulfate ester aluminum salt, which are conventionally known to have anti-ulcer effects, were used as comparative compounds. Experiment 1 Effect on pylorus ligation ulcer: 1 group of male rats weighing 210-230g
The number was 10. Stay et al. (Gastroenterology, 5,
43-61, 1945), fast for 48 hours, and ligate the pylorus under ether anesthesia. After 14 hours of fasting and water deprivation, the stomach was removed and gastric juice was collected.The area (mm 2 ) of ulcers occurring in the forestomach was measured under a dissecting microscope (10x magnification) and expressed as an ulcer index. . Drugs were administered orally immediately after pylorus ligation. The results are shown in Table 1. [Table] As is clear from the above experimental results, the N of the present invention
- Acylcarnosine aluminum salts show excellent inhibitory effects on ulcer models. In other words, in the pyloric ligation ulcer test, when N-acylcarnosine aluminum salt was orally administered to rats at a dose of 1000/Kg, it showed a significant inhibitory effect on ulcers, and compared with existing anti-ulcer drugs, it was comparable. or even more effective. Hereinafter, the present invention will be explained in more detail with reference to Reference Examples and Examples, but the present invention is not limited thereto. Reference example 1 N-propionyl-L-carnosine: Dissolve 2.42 g of L-carnosine in 13 ml of water, add 6.5 ml of acetone, cool it, and adjust the pH at below 20°C.
Propionyl chloride 4.14 while keeping it between 7.0 and 7.5.
g and 7.6 g of triethylamine were simultaneously added dropwise over a period of about 1 hour. After the dropwise addition, the acetone is distilled off under reduced pressure, and the strongly basic ion exchange resin (SA-10A) 130
ml, washed with water and eluted with 1N acetic acid, then adsorbed on 10 ml of strongly acidic ion exchange resin (SK-1B), washed with water, and eluted with 2% aqueous ammonia. Concentrate under reduced pressure to remove most of the ammonia, then pass through 30 ml of weakly acidic ion exchange resin (IRC-50), collect the unadsorbed portion and dry under reduced pressure to obtain crude crystals. This was recrystallized with a mixed solvent of methanol-acetone (2:3) to obtain N-propionyl-L-
1.46 g (yield 48%) of white crystals of carnosine was obtained. Melting point: 206-209℃ (decomposition) [α] 25 D : +20.4゜ (C = 3%, water) IRν KBr nax cm -1 : 3300 (OH), 1630 (C = 0), 1540,
1390 NMR (D 2 O) δ: 1.06 (3H, t, J = 8Hz, -
CH 2 C H 3 ) 2.18 (2H, q, J=8Hz, -C
H 2 CH 3 ) 2.44 (2H, t, J=7Hz, -
NHCOC H 2 CH 2 NH―) 3.14 (2H, m,
[Formula]) 3.36 (2H, t, J=7Hz, -
NHCOCH 2 C H 2 NH―) 4.44 (1H, m,
[Formula]) 7.08, 8.48 (1H×2, s×2,
Imitazole ring proton) Elemental analysis value C 12 H 18 N 4 O 4 Calculated value (%) C: 51.04, H: 6.44, N: 19.85 Analysis value (%) C: 50.95, H: 6.43, N: 19.77 Reference example 2 N-heptanoyl-L-carnosine Dissolve 2.42 g of L-carnosine in 13 ml of water, add 6.5 ml of acetone, replace propionyl chloride with 6.36 g of heptanoyl chloride, and use the same method as in Reference Example 1.
Coarse crystals are obtained by treatment with an ion exchange resin. By recrystallizing this with a mixed solvent of water and acetone (1:2), N-heptanoyl-
1.66 g (yield 46%) of L-carnosine was obtained. Melting point: 214-217°C (decomposed) [α] 25 D : +4.7° = (C = 2%, water) IRν KBr nax cm -1 : 3290, 1635, 1530, 1400 NMR (D 2 O) δ: 0.72 (3H, m, -C H 3 ) 0.86~1.56 (8H, m,
[Formula]) 2.06 (2H, t, J=7Hz, -
COC H 2 CH 2 -) 2.35 (2H, t, J=7Hz, -
NHCOC H 2 CH 2 NH) 2.94~3.14 (2H, m,
[Formula]) 3.26 (2H, t, J=7Hz, -
NHCOCH 2 C H 2 NH) 4.26~4.44 (1H, m,
[Formula]) 7.10, 8.42 (1H×2, s×2,
(imidazole ring proton) Elemental analysis value C 16 H 26 N 4 O 4 Calculated value (%) C: 56.77, H: 7.76, N: 16.56 Analysis value (%) C: 56.81, H: 7.85, N: 16.38 Reference example 3 N-benzoyl-L-carnosine Dissolve 2.42 g of L-carnosine in 13 ml of water, add 6.5 ml of acetone, replace propionyl chloride with 6.32 g of benzoyl chloride, and perform ion exchange resin treatment in the same manner as in Reference Example 1. The resulting crude crystals were recrystallized with methanol-acetone to obtain N-benzoyl-L.
-1.69 g of carnosine (yield 48%) was obtained. Melting point: 217-219℃ (decomposed) [α] 25 D : +10.3゜ (C = 1%, water) IRν KBr nax cm -1 : 3280, 1640, 1520, 1385 NMR (D 2 O) δ: 2.48 (2H, t, J=7Hz, -
COC H 2 CH 2 NH―) 3.02 (2H, m,
[Formula]) 3.46 (2H, t, J=7Hz, -
COCH 2 C H 2 NH―) 4.37 (1H, m,
[Formula]) 6.99 [1H, s, imidazole ring proton (5th position)] 7.1-7.6 (5H, m, benzene ring proton) 8.14 [1H, s, imidazole ring proton (2nd position)] Elemental analysis value C 16 H As 18 N 4 O 4 Calculated value (%) C: 58.16, H: 5.50, N: 16.96 Analytical value (%) C: 58.21, H: 5.65, N: 16.93 Reference example 4 N-(O-methoxy)benzoyl- L-Carnosine: Dissolve 2.42 g of L-carnosine in 13 ml of water, add 6.5 ml of acetone, and use 7.67 g of O-methoxybenzoyl chloride instead of propionyl chloride, perform ion exchange resin treatment and concentrate in the same manner as in Reference Example 1. Dry. This material is very hygroscopic and cannot be recrystallized, and the crude crystals are washed with anhydrous ether to give a white powder of N-
(O-methoxybenzoyl)-L-carnosine
1.54 (yield 40%) was obtained. Melting point: 203℃ (decomposition) [α] 25 D : 7.6゜ (C = 1%, water) IRν KBr nax cm -1 : 3380, 1630 NMR (CD 3 OD) δ: 2.56 (2H, t, J = 7Hz ,
―COC H 2 CH 2 NH―) 3.16 (2H, m,
[Formula]) 3.60 (2H, t, J=7Hz, -
COCH 2 C H 2 NH-) 3.86 (3H, s, -OC H 3 ) 4.55 (1H, m,
[Formula]) 6.85-7.85 [5H, m, benzene ring proton and imidazole ring proton (2nd position)] 8.33 [1H, s, imidazole ring proton (2nd position)] Elemental analysis Calculated as C 17 H 20 N 4 O 5 Value (%) C: 56.65, H: 5.60, N: 15.55 Analytical value (%) C: 56.61, H: 5.58, N: 15.61 Example 1 Add 11 ml of isopropyl alcohol containing 0.80 g of aluminum isopropoxide at 60°C. 1.11 g of N-propionyl-L-carnosine was added, and after stirring for 1 hour, 10 ml of water was added and stirred for 30 minutes to obtain a homogeneous solution. Thereafter, insoluble matter was separated, isopropyl alcohol was distilled off under reduced pressure, and the remaining aqueous solution was freeze-dried to obtain 1.3 g (quantitative) of N-propionyl-L-carnosine aluminum salt as a colorless powder. Melting point: 228℃ (decomposition) [α] 25 D : +11.4゜ (C = 3%, water) IRν KBr nax cm -1 : 3400 (OH), 1640 (C = 0), 1540,
1400 NMR (D 2 O) δ: 1.02 (3H, t, CH 3 CH 2 CO
―) 2.11 (2H, q, CH 3 C H 2 CO―) 2.40 (2H, t, ―COC H 2
CH 2 NH―) 3.08 (2H, m,
[Formula]) 3.28 (2H, t, - COCH 2 C H 2
NH―) 4.44 (1H, m,
[Formula]) 7.07, 8.26 (1H×2, s×2,
(imidazole ring proton) Elemental analysis (C 12 H 17 N 4 O 4 ) as Al(CH) 2 Calculated value (%) C: 42.10, H: 5.61, N: 16.37 Analysis value (%) C: 41.88, H: 5.83 ,N:16.12 Example 2 N-heptanoyl in 15 ml of isopropyl alcohol containing 0.68 g of aluminum isopropoxide
1.13 g of L-carnosine was added and the same procedure as in Example 1 was carried out to obtain 1.3 g (quantitative) of colorless powder of N-heptanoyl-L-carnosine aluminum salt. Melting point: 280°C or higher [α] 25 D : +0.4° (C = 1%, water) IRν KBr nax cm -1 : 3400 (OH), 2930, 2860 (alkyl), 1640 (C = 0), 1540 NMR (D 2 O) δ: 0.80 (3H, t, CH 3 - CH 2
--) 1.20 (8H, m, --CH 2 --×4) 2.12 (2H, t, --CH 2 C H 2 CO
--) 2.40 (2H, t, --COC H 2
CH 2 NH―) 3.07 (2H, m,
[Formula]) 3.31 (2H, t, - COCH 2 C H 2
NH―) 4.44 (1H, m,
[Formula]) 7.06, 8.28 (1H×2, s×2,
(imidazole ring proton) Elemental analysis C 16 H 25 N 4 O 4 ) As Al(OH) 2 Calculated value (%) C: 48.23, H: 6.84, N: 14.06 Analysis value (%) C: 48.03, H: 6.87, N: 13.77 Example 3 N-benzoyl-L in 15 ml of isopropyl alcohol containing 0.8 g of aluminum isopropoxide
- 1.27 g of carnosine was added and treated in the same manner as in Example 1 to obtain 1.5 g (quantitative) of colorless powder of N-benzoyl-L-carnosine aluminum salt. Melting point: 280°C or higher [α] 25 D : +6.2° (C = 1%, H 2 O) IRν KBr nax cm -1 : 3400 (OH), 1630 (C = 0), 1540,
1400 NMR (D 2 O) δ: 2.55 (2H, t, - COC H 2
CH 2 NH―) 3.07 (2H, m,
[Formula]) 3.55 (2H, t, - COCH 2 C H 2
NH―) 4.44 (1H, m,
[Formula]) 6.99 [1H, s, imidazole ring proton (5th position)] 7.44 (5H, m, benzene ring proton) 8.08 [1H, s, imidazole ring proton (2nd position)] Elemental analysis (C 16 H 17 N 4 O 4 )Al(OH) Calculated value (%) as 2 C: 49.23, H: 4・92, N:
14.36 Analysis value (%) C: 49.18, H: 4.86, N: 14.18 Example 4 1.20 g of N-(O-methoxy)benzoyl-L-carnosine was added to 15 ml of isopropyl alcohol containing 0.68 g of aluminum isopropoxide and treated in the same manner as in Example 1 to obtain N-(O-methoxy)-
L-carnosine aluminum salt 1.4g (quantitative)
I got it. Melting point: 280°C or higher [α] 25 D : +2.7° (C = 1%, water) IRν KBr nax cm -1 : 3400 (OH), 1630 (C = 0), 1540,
1400, 1310 NMR (D 2 O) δ: 2.56 (2H, t, - COC H 2
CH 2 NH―) 3.29 (2H, m,
[Formula] 3.55 (2H, t, - COCH 2 C H 2
NH―) 3.83 (3H, s, -OC H 3 ) 4.44 (1H, m,
[Formula]) 6.95-7.65 (5H, m, benzene ring proton and imidazole ring proton) 7.96 (1H, s, imidazole ring proton) Elemental analysis (C 17 H 19 N 4 O 5 ) Al (OH) 2 Calculated value ( %) C: 48.57, H: 5.05, N: 13.33 Analysis value (%) C: 48.42, H: 4.92, N: 13.18

Claims (1)

【特許請求の範囲】 1 一般式 (式中、Rは炭素数2〜6の低級アルキル基、フ
エニル基または低級アルコキシフエニル基を表わ
す。) で表わされるN―アシルカルノシンアルミニウム
塩。
[Claims] 1. General formula (In the formula, R represents a lower alkyl group having 2 to 6 carbon atoms, a phenyl group, or a lower alkoxyphenyl group.) N-acyl carnosine aluminum salt represented by:
JP55136781A 1980-10-02 1980-10-02 N-acylcarnosine aluminum salt and its preparation Granted JPS5762263A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP55136781A JPS5762263A (en) 1980-10-02 1980-10-02 N-acylcarnosine aluminum salt and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55136781A JPS5762263A (en) 1980-10-02 1980-10-02 N-acylcarnosine aluminum salt and its preparation

Publications (2)

Publication Number Publication Date
JPS5762263A JPS5762263A (en) 1982-04-15
JPH0135828B2 true JPH0135828B2 (en) 1989-07-27

Family

ID=15183361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55136781A Granted JPS5762263A (en) 1980-10-02 1980-10-02 N-acylcarnosine aluminum salt and its preparation

Country Status (1)

Country Link
JP (1) JPS5762263A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6314728A (en) * 1986-07-03 1988-01-21 Zeria Shinyaku Kogyo Kk Preventive and remedy for hepatic disorder
US4882324A (en) * 1986-11-21 1989-11-21 Wright Arthur P G Essentially pure acid hydroxyl ligand aluminum complexes and their preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6350352A (en) * 1986-08-18 1988-03-03 製錬新基盤技術研究組合 Automatic blowing manufacture of molten slag

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6350352A (en) * 1986-08-18 1988-03-03 製錬新基盤技術研究組合 Automatic blowing manufacture of molten slag

Also Published As

Publication number Publication date
JPS5762263A (en) 1982-04-15

Similar Documents

Publication Publication Date Title
US4412992A (en) 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
JPS63264442A (en) Lipoxygenase inhibitive compound
JPS6229566A (en) Novel guanidinomthylbenzoic acid derivative
IE54896B1 (en) Pyrrolacetic amides having antiinflammatory activity
CA2091256A1 (en) Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5607930A (en) 1,4-disubstituted piperazines useful in the therapy of the asthma and of the inflammation of the respiratory tract
JPH0546343B2 (en)
JPH0135828B2 (en)
CA1151183A (en) N-acylcarnosine aluminum salt, its preparation, and a digestive ulcer remedy containing such salt
EP0086126A1 (en) Imidazoline derivatives, their preparation and therapeutical application
KR880002594B1 (en) Process for preparing n-carboxyalkylproline-containing tripeptides
EP0403828A1 (en) Renin-inhibiting peptides, their preparation and their use in medicaments
CA1025865A (en) Process for preparing new heterocyclic amides
EP0559190A1 (en) Substituted N- 3- 3-(1-piperinomethyl)-phenoxy propyl actamides as antiuocer drugs
US4339378A (en) N-Acylcarnosine aluminum salts
EP0055145B1 (en) 4-(aminomethyl)cyclohexane-1-carboxylic acid derivatives
JPH0135829B2 (en)
JPS6251951B2 (en)
JP2589245B2 (en) N- (3-alkyl (or alkenyl) -4-hydroxybenzoyl) glycine zinc complex
US4005084A (en) Thienylmethyl phenoxy morpholine compounds
EP0185158A1 (en) Diphenylmethylimine derivatives
JPS6330462A (en) Novel guanidinomethylbenzamide derivative and antiulcer agent containing said derivative as active ingredient
JPS6316382B2 (en)
US4339379A (en) N-Acrylcarnosine aluminum salts
EP0192317B1 (en) Homocarnosine or acylhomocarnosine salts